Literature DB >> 16223941

In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.

T Piercy1, J Steward, M S Lever, T J G Brooks.   

Abstract

OBJECTIVES: The in vivo efficacy of ciprofloxacin, gatifloxacin and moxifloxacin were assessed in an experimental Francisella tularensis Schu S4 infection in the BALB/c mouse model.
METHODS: Mice were given 100 mg/kg of antibiotic by oral administration twice daily commencing at 6, 24 or 48 h post-exposure and continued for 14 days post-exposure. All mice were challenged subcutaneously with 1 x 10(6) cfu F. tularensis Schu S4 and observed for a period of 56 days.
RESULTS: Treatment initiated 6 h post-exposure resulted in 94, 100 and 100% survival for ciprofloxacin, gatifloxacin and moxifloxacin, respectively. When treatment was delayed until 24 h post-exposure the survival rates were ciprofloxacin 67%, gatifloxacin 96% and moxifloxacin 100%. Treatment initiated at 48 h post-exposure resulted in a significant reduction in the survival rate of the ciprofloxacin-treated mice, with 0% survival compared with 84 and 62% for gatifloxacin and moxifloxacin, respectively. Non-treated infected control mice died within 96 h post-exposure. Dexamethasone given at day 42 for 7 days to suppress the animals' immune system caused relapse in all of the treatment groups.
CONCLUSIONS: Both gatifloxacin and moxifloxacin were more effective at preventing mortality than ciprofloxacin and could be considered as alternative antibiotics in the treatment of systemic F. tularensis infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223941     DOI: 10.1093/jac/dki359

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Authors:  Karleigh A Hamblin; Stuart J Armstrong; Kay B Barnes; Carwyn Davies; Jonathan P Wong; James D Blanchard; Sarah V Harding; Andrew J H Simpson; Helen S Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

2.  Mouse models of aerosol-acquired tularemia caused by Francisella tularensis types A and B.

Authors:  David L Fritz; Marilyn J England; Lynda Miller; David M Waag
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

3.  Modeling inhalational tularemia: deliberate release and public health response.

Authors:  Joseph R Egan; Ian M Hall; Steve Leach
Journal:  Biosecur Bioterror       Date:  2011-11-01

4.  Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain.

Authors:  George Aperis; Beth Burgwyn Fuchs; Christine A Anderson; John E Warner; Stephen B Calderwood; Eleftherios Mylonakis
Journal:  Microbes Infect       Date:  2007-02-24       Impact factor: 2.700

5.  Targeting the "Rising DAMP" during a Francisella tularensis Infection.

Authors:  Riccardo V D'Elia; Thomas R Laws; Alun Carter; Roman Lukaszewski; Graeme C Clark
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

6.  Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia.

Authors:  Marjorie D Sutherland; Andrew W Goodyear; Ryan M Troyer; Jeffrey C Chandler; Steven W Dow; John T Belisle
Journal:  Vaccine       Date:  2012-05-28       Impact factor: 3.641

7.  A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.

Authors:  Charlotte A Hall; Helen C Flick-Smith; Sarah V Harding; Helen S Atkins; Richard W Titball
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.

Authors:  Kathleen England; Christopher am Ende; Hao Lu; Todd J Sullivan; Nicole L Marlenee; Richard A Bowen; Susan E Knudson; Dennis L Knudson; Peter J Tonge; Richard A Slayden
Journal:  J Antimicrob Chemother       Date:  2009-09-04       Impact factor: 5.790

9.  Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody.

Authors:  Gary R Klimpel; Tonyia Eaves-Pyles; Scott T Moen; Joanna Taormina; Johnny W Peterson; Ashok K Chopra; David W Niesel; Paige Carness; Judith L Haithcoat; Michelle Kirtley; Abdelhakim Ben Nasr
Journal:  Vaccine       Date:  2008-10-16       Impact factor: 3.641

10.  Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.

Authors:  Shahar Rotem; Erez Bar-Haim; Hila Cohen; Uri Elia; Raphael Ber; Avigdor Shafferman; Ofer Cohen
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.